| scholarly article | Q13442814 |
| P50 | author | Marcin Moniuszko | Q30902433 |
| Jay A Berzofsky | Q61160082 | ||
| Mark G. Lewis | Q66732036 | ||
| P2093 | author name string | Warren Strober | |
| Vladimir A Kuznetsov | |||
| Genoveffa Franchini | |||
| Igor M Belyakov | |||
| John D Clements | |||
| Phillip D Markham | |||
| Ranajit Pal | |||
| Brian Kelsall | |||
| Dennis Klinman | |||
| Michael Lemon | |||
| P2860 | cites work | CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract | Q22242965 |
| Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract | Q22242981 | ||
| Phenotypic analysis of antigen-specific T lymphocytes | Q28290058 | ||
| Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 | ||
| Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection | Q29619099 | ||
| Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections | Q33776155 | ||
| A rational basis for mucosal vaccination against HIV infection | Q33776167 | ||
| Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. | Q33784928 | ||
| Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation | Q33814150 | ||
| CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing | Q33835440 | ||
| A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L | Q34191248 | ||
| Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types | Q34197974 | ||
| ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency | Q34326613 | ||
| Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. | Q34355037 | ||
| Strategies for designing and optimizing new generation vaccines | Q34572198 | ||
| The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? | Q34632089 | ||
| Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines | Q35109075 | ||
| Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity | Q35130248 | ||
| Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses | Q35234767 | ||
| Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines | Q35696885 | ||
| Molecular mechanisms and biological significance of CTL avidity | Q35716722 | ||
| Present status of human HIV vaccine development | Q35744225 | ||
| Mucosal AIDS vaccines: current status and future directions | Q35851782 | ||
| Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques | Q35860556 | ||
| Progress on new vaccine strategies against chronic viral infections | Q35864857 | ||
| Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge | Q35884740 | ||
| Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques | Q36366154 | ||
| Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. | Q36368095 | ||
| Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex | Q36400759 | ||
| Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides | Q36400848 | ||
| Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques | Q36546178 | ||
| Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells | Q37221714 | ||
| The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. | Q37388157 | ||
| IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. | Q37589836 | ||
| Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. | Q37629901 | ||
| High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. | Q40830770 | ||
| NYVAC: a highly attenuated strain of vaccinia virus | Q41626050 | ||
| Selective induction of high avidity CTL by altering the balance of signals from APC. | Q42804988 | ||
| Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. | Q42833971 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion | Q45124959 | ||
| Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. | Q45543090 | ||
| Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses | Q45730388 | ||
| Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection | Q45732713 | ||
| Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity | Q45734062 | ||
| Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology | Q45743923 | ||
| Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. | Q45755361 | ||
| Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | Q56774528 | ||
| Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells | Q57075707 | ||
| Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques | Q57089572 | ||
| HIV-1 expression in chimpanzees can be activated by CD8+ cell depletion or CMV infection | Q67507345 | ||
| Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes | Q73224720 | ||
| A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing | Q74150972 | ||
| CpG oligodeoxynucleotides as vaccine adjuvants in primates | Q77584362 | ||
| Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa | Q77787637 | ||
| Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration | Q78402667 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 3258-3264 | |
| P577 | publication date | 2005-12-22 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa | |
| P478 | volume | 107 |
| Q30379637 | 25 years of HIV research! ... and what about a vaccine? |
| Q35628697 | A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations |
| Q43135807 | AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection |
| Q37472898 | An African perspective on mucosal immunity and HIV-1. |
| Q37184070 | CD8+ T cell efficacy in vaccination and disease |
| Q37543246 | CTL quality and the control of human retroviral infections |
| Q27022152 | Challenges in mucosal HIV vaccine development: lessons from non-human primate models |
| Q35066293 | Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. |
| Q36780136 | Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity |
| Q45405375 | Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine design, immunogenicity and toxicity studies |
| Q34616275 | Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques |
| Q28487823 | Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells |
| Q46885202 | Construction of recombinant Lactobacillus casei efficiently surface displayed and secreted porcine parvovirus VP2 protein and comparison of the immune responses induced by oral immunization |
| Q38086157 | Crosstalk between adaptive and innate immune cells leads to high quality immune protection at the mucosal borders |
| Q34502108 | Current progress in the development of a prophylactic vaccine for HIV-1. |
| Q42185673 | Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity |
| Q36943319 | Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments |
| Q45262997 | Effective vaginal DNA delivery with high transfection efficiency is a good system for induction of higher local vaginal immune responses |
| Q45325097 | Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1. |
| Q38330358 | Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. |
| Q42258701 | Evaluation of virus-specific cellular immune response in transplant patients. |
| Q38066211 | Functional avidity: a measure to predict the efficacy of effector T cells? |
| Q36663607 | Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization |
| Q37590335 | Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity |
| Q33535905 | HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity |
| Q34601874 | HIV infection and the gastrointestinal immune system |
| Q33565035 | HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers |
| Q37344236 | HIV/AIDS vaccines: a need for new concepts? |
| Q35214354 | High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection |
| Q35192655 | High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q37801269 | Human immunodeficiency virus-1 vaccine design: where do we go now? |
| Q33915690 | Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses |
| Q42277634 | IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8⁺ T cell avidity following HIV-1 recombinant pox viral vaccination. |
| Q40372613 | Identification of biomarkers to measure HIV-specific mucosal and systemic CD8(+) T-cell immunity using single cell Fluidigm 48.48 Dynamic arrays. |
| Q34575451 | Immune mechanisms of HIV control |
| Q44437034 | Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity |
| Q81582230 | Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration |
| Q27001897 | Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection |
| Q34641666 | Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations |
| Q33761198 | Induction of resident memory T cells enhances the efficacy of cancer vaccine |
| Q43657076 | Influenza epitope-specific CD8+ T cell avidity, but not cytokine polyfunctionality, can be determined by TCRβ clonotype |
| Q34006329 | Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques |
| Q45367797 | Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4+ and CD8+ T cells in the genital and intestinal tracts |
| Q33265482 | Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection |
| Q34099837 | Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization |
| Q34060493 | Memories that last forever: strategies for optimizing vaccine T-cell memory |
| Q42252024 | Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans |
| Q104486611 | Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques |
| Q92889493 | Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission |
| Q64074435 | Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques |
| Q81363573 | Mucosal immunity and HIV/AIDS vaccines. Report of an International Workshop, 28-30 October 2007 |
| Q30375160 | Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. |
| Q33862822 | Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors |
| Q38772796 | Mucosal memory CD8⁺ T cells are selected in the periphery by an MHC class I molecule |
| Q64127566 | Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses |
| Q36978334 | Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. |
| Q37594498 | Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. |
| Q34274849 | New approaches to design HIV-1 T-cell vaccines |
| Q35575565 | Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCRalphabeta(+) CD8alphabeta(+) T cells in the small intestinal mucosa |
| Q26861148 | Nonhuman primate models for HIV/AIDS vaccine development |
| Q42198317 | Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy. |
| Q38168900 | Novel approaches in polyepitope T-cell vaccine development against HIV-1. |
| Q81937261 | Oral polio vaccination leads to oligoclonal expansion of TCRBV16+ and TCRBV13+ T cells in the colon of rhesus macaques |
| Q38265356 | Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development |
| Q46858687 | Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study |
| Q34552488 | Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV. |
| Q36758574 | Problems and emerging approaches in HIV/AIDS vaccine development |
| Q40058510 | Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine |
| Q36951735 | Public T cell receptors confer high-avidity CD4 responses to HIV controllers |
| Q35140438 | Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge |
| Q37554135 | Strategies for optimizing targeting and delivery of mucosal HIV vaccines |
| Q51601960 | Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. |
| Q33826671 | T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge |
| Q35672335 | TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques |
| Q30386549 | Targeting early infection to prevent HIV-1 mucosal transmission. |
| Q43477258 | Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses |
| Q37476108 | The European effort towards the development of mucosal vaccines for poverty-related diseases |
| Q57945015 | The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT |
| Q28481573 | Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques |
| Q46391524 | Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. |
| Q37803319 | Update on mucosal HIV vaccine vectors |
| Q33609436 | Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice |
| Q33685961 | Vaccine-induced myeloid cell population dampens protective immunity to SIV |
| Q91408185 | Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes |
| Q35963420 | Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3). |
Search more.